Diclofenac transdermal first generation - Crescita Therapeutics

Drug Profile

Diclofenac transdermal first generation - Crescita Therapeutics

Alternative Names: Diclofenac transdermal 1.5%; Pennsaid

Latest Information Update: 02 Sep 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nuvo Research
  • Developer Endo International; Nuvo Research
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal pain

Most Recent Events

  • 20 Aug 2015 Novu Research receives patent allowance for topical foamed formulations including DMSO in USA
  • 31 Jan 2015 Withdrawn for Musculoskeletal pain in USA (Transdermal) prior to January 2015
  • 17 Oct 2014 Diclofenac transdermal first generation is no longer licensed to Mallinkrodt in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top